A Multicenter, Open-label Evaluation of Treatment Satisfaction, Tolerability, Safety and Preference for Sumavel DosePro for Treatment of Migraine in Subjects Dissatisfied With Their Existing Triptan Therapy.

Trial Profile

A Multicenter, Open-label Evaluation of Treatment Satisfaction, Tolerability, Safety and Preference for Sumavel DosePro for Treatment of Migraine in Subjects Dissatisfied With Their Existing Triptan Therapy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Oct 2015

At a glance

  • Drugs Sumatriptan (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Sponsors Zogenix
  • Most Recent Events

    • 28 Dec 2011 Actual patient numbers changed from 212 to 246 as reported by ClinicalTrials.gov.
    • 04 Aug 2011 Secondary endpoint 'Patient confidence' has been met.
    • 04 Aug 2011 Primary endpoint 'Patient-satisfaction' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top